gemcitabine + oxaliplatin + eribulin

This is a combination chemotherapy regimen consisting of three cytotoxic agents—gemcitabine, oxaliplatin, and eribulin. Each drug has a distinct mechanism of action targeting cancer cell proliferation: - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase, leading to apoptosis in rapidly dividing cells[3][9]. - **Oxaliplatin** is a platinum-based compound that forms DNA adducts, causing crosslinking and subsequent inhibition of DNA replication and transcription[9]. - **Eribulin** is a microtubule dynamics inhibitor (a synthetic analog of halichondrin B) that binds to the plus ends of microtubules, preventing their growth and ultimately causing mitotic arrest and apoptosis[4][2]. While gemcitabine plus oxaliplatin (GemOx) is an established combination for various solid tumors such as pancreatic cancer, biliary tract cancers, germ cell tumors, and others[6][8][9], eribulin has demonstrated efficacy as monotherapy or in dual combinations (notably with gemcitabine) for metastatic breast cancer and soft tissue sarcomas including liposarcoma[1][4]. Preclinical studies have shown additive or synergistic antitumor activity when eribulin is combined with other cytotoxic agents like gemcitabine or platinum compounds in several tumor models[2]. However, there are no published clinical trials specifically evaluating the triple combination "gemcitabine + oxaliplatin + eribulin" as a single regimen; its use would be considered investigational.